Log in

Relevant bibliographies by topics / Agnostic antibody

Contents

Journal articles
Book chapters

Academic literature on the topic 'Agnostic antibody'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Agnostic antibody.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Agnostic antibody"

1

van Vloten, Jacob P., Elaine M. Klafuric, Khalil Karimi, et al. "Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies." Molecular Therapy - Methods & Clinical Development 14 (September 2019): 189–96. http://dx.doi.org/10.1016/j.omtm.2019.06.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dias e Silva, Douglas, Guilherme Malandrini Andriatte, and Roberto Carmagnani Pestana. "Antibody-Drug Conjugates and Tissue-Agnostic Drug Development." Cancer Journal 28, no. 6 (2022): 462–68. http://dx.doi.org/10.1097/ppo.0000000000000633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Thein, Kyaw Z., Yin M. Myat, Byung S. Park, Kalpana Panigrahi, and Shivaani Kummar. "Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development." Cancers 16, no. 14 (2024): 2529. http://dx.doi.org/10.3390/cancers16142529.

Full text

Abstract:

The regulatory approvals of tumor-agnostic therapies have led to the re-evaluation of the drug development process. The conventional models of drug development are histology-based. On the other hand, the tumor-agnostic drug development of a new drug (or combination) focuses on targeting a common genomic biomarker in multiple cancers, regardless of histology. The basket-like clinical trials with multiple cohorts allow clinicians to evaluate pan-cancer efficacy and toxicity. There are currently eight tumor agnostic approvals granted by the Food and Drug Administration (FDA). This includes two im

APA, Harvard, Vancouver, ISO, and other styles

4

Abelman, R., L. M. Spring, R. Corcoran, and A. Bardia. "Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child." Annals of Oncology 34, no. 11 (2023): 968–69. http://dx.doi.org/10.1016/j.annonc.2023.10.115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chin, Amanda, Rubin Jiao, Kevin J. H. Allen, et al. "Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, Targets AML in a Mutation Agnostic Manner." Blood 142, Supplement 1 (2023): 5750. http://dx.doi.org/10.1182/blood-2023-187498.

Full text

Abstract:

Introduction Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy with a poor survival prognosis. Recurrent gene mutations are the major obstacle that impact treatment efficacy of AML patients. Actimab-A, an anti-CD33 antibody conjugated with Actinium-225 (Ac-225) alpha particle-emitting radionuclide (lintuzumab-Ac225), has demonstrated promising therapeutic responses in AML patients, including in combination trials with chemotherapy regimen CLAG-M and targeted therapy venetoclax. Because lintuzumab-Ac225 broadly targets myeloid cells via CD33, we hypothesized that ant

APA, Harvard, Vancouver, ISO, and other styles

6

Savard, Marie-France, Omar Khan, Kelly K. Hunt, and Sunil Verma. "Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer." American Society of Clinical Oncology Educational Book, no. 39 (May 2019): e8-e21. http://dx.doi.org/10.1200/edbk_237419.

Full text

Abstract:

Although not considered curative in nature, new therapeutic advances in metastatic breast cancer (MBC) have substantially improved patient outcomes. This article discusses the state-of-the-art and emerging therapeutic options for management of MBC. BC systemic therapy targets multiple key pathways, including estrogen receptor signaling, HER2 signaling, and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling. Other therapeutic strategies include targeting DNA repair, inhibiting immune checkpoints, and developing antibody-drug conjugates. Althou

APA, Harvard, Vancouver, ISO, and other styles

7

Zhang, Ruijun, Ponraj Prabakaran, Xiaocong Yu, et al. "A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies." mAbs 13, no. 1 (2021): 1904546. http://dx.doi.org/10.1080/19420862.2021.1904546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lanzavecchia, Antonio. "Dissecting Human Antibody Responses: Useful, Basic, and Surprising Findings." Blood 130, Suppl_1 (2017): SCI—49—SCI—49. http://dx.doi.org/10.1182/blood.v130.suppl_1.sci-49.sci-49.

Full text

Abstract:

Abstract We use cell culture-based high-throughput methods to interrogate human memory B cell and plasma cell repertoires and to isolate antibodies selected on the basis of their neutralizing potency and breadth. Relevant examples are antibodies that neutralize all influenza A viruses or even four paramyxoviruses. By targeting conserved structures, these broadly neutralizing antibodies are less prone to select escape mutants and are promising candidates for prophylaxis and therapy of infections, as well as tools for vaccine design. The value of a target-agnostic approach to vaccine design is i

APA, Harvard, Vancouver, ISO, and other styles

9

Hong, Wan Xing, Idit Sagiv-Barfi, Debra K. Czerwinski, Adrienne Sallets, and Ronald Levy. "Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer." Cancer Research 82, no. 7 (2022): 1396–408. http://dx.doi.org/10.1158/0008-5472.can-21-1382.

Full text

Abstract:

Abstract The combination of the synthetic TLR9 ligand CpG and agnostic OX40 antibody can trigger systemic antitumor immune responses upon co-injection into the tumor microenvironment, eradicating simultaneous untreated sites of metastatic disease. Here we explore the application of this in situ immunotherapy to the neoadjuvant setting. Current neoadjuvant checkpoint blockade therapy is delivered systemically, resulting in off-target adverse effects. In contrast, intratumoral immunotherapy minimizes the potential for toxicities and allows for greater development of combination therapies. In two

APA, Harvard, Vancouver, ISO, and other styles

10

Kok, Marleen, Myriam Chalabi, and John Haanen. "How I treat MSI cancers with advanced disease." ESMO Open 4, Suppl 2 (2019): e000511. http://dx.doi.org/10.1136/esmoopen-2019-000511.

Full text

Abstract:

Mismatch repair deficiency (dMMR) results in microsatellite instability (MSI) and is strongly associated with responsiveness to programmed death-1 receptor (PD-1)-blocking antibodies. Probably the main driver for the observed high efficacy of immune checkpoint inhibitors in dMMR tumours is the remarkably high tumour mutational burden. MSI can be detected using immunohistochemistry and/or PCR. In addition, next-generation sequencing is becoming increasingly available to clinical laboratories as a cost-effective and scalable method to evaluate multiple genetic aberrations including MSI. Efficacy

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Agnostic antibody"

1

Peabody, Julianne, Susan B. Core, Larance Ronsard, Daniel Lingwood, David S. Peabody, and Bryce Chackerian. "An Approach for Antigen-Agnostic Identification of Virus-Like Particle-Displayed Epitopes that Engage Specific Antibody V Gene Regions." In Methods in Molecular Biology. Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3469-1_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lambourne, Jonathan, and Ruaridh Buchanan. "Immunotherapy." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0057.

Full text

Abstract:

Immunotherapy implies the use of an immune-based therapy to treat infection. Broadly speaking, these therapies can be divided into antibody-based therapies (both pathogen specific and pathogen agnostic), cellular therapies (e.g. CMV-specific T cells), and immune signalling therapies (e.g. interferon-alpha in the treatment of hepatitis C infection). While agents such as corticosteroids, thalidomide, and vitamin D have profound effects on immune function and a well-established role in the treatment of some infections (e.g. corticosteroids in tuberculous and pneumococcal meningitis), in this revi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!